U.S. markets closed

Pharming Group N.V. (PHAR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.69+0.09 (+0.85%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close10.60
Bid5.25 x 1100
Ask10.72 x 1000
Day's Range9.95 - 10.76
52 Week Range6.10 - 12.98
Avg. Volume3,444
Market Cap709.573M
Beta (5Y Monthly)1.15
PE Ratio (TTM)36.86
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
41% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PHAR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Pharming Group N.V.
    Daily – Vickers Top Buyers & Sellers for 12/20/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • CNW Group

    Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

    Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that the US Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, to treat the rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older in the US. The FDA has assigned a Prescription

  • PR Newswire

    CEO of Pharming to present at H.C. Wainwright 24th Annual Global Investment Conference

    Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that its Chief Executive Officer, Sijmen de Vries, will present at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid meeting based in New York, at the Lotte Palace Hotel, September 12-14, 2022.

  • PR Newswire

    Pharming Group reports financial results for the first half of 2022

    Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) presents its preliminary (unaudited) financial report for the first six months of 2022 ended June 30, 2022.